THE 60-SECOND GUIDE
Tirzepatide
Approved human use · product-specific labels.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
Tirzepatide acts at both GIP and GLP-1 receptors, pathways involved in glucose regulation and appetite. Mounjaro and Zepbound contain the same molecule but have separate approved indications and product labels. [1]
Potential benefits
Mounjaro is FDA-approved to improve glycemic control in people with type 2 diabetes under its current label. Zepbound is FDA-approved under separate labeling for chronic weight management and obstructive sleep apnea in adults with obesity. Clinical evidence must be matched to the exact product, population, indication, and outcome studied. [1]
Evidence & its limits
The boxed warning concerns thyroid C-cell tumors observed in rats; whether tirzepatide causes these tumors in humans is unknown. Gastrointestinal reactions, contraindications, and other warnings require the exact product label. Approval does not extend automatically to unapproved copies or other uses. [1]
Risks & unknowns
Gastrointestinal adverse reactions are common and can be serious. Current labels include a boxed warning about thyroid C-cell tumors observed in rats; relevance to humans is unknown. Contraindications and additional warnings apply under the product-specific labeling. Approved products must be distinguished from unapproved or counterfeit copies. [1]
Status & scope
Mounjaro and Zepbound contain the same molecule but have separate approved indications and product labels. Approved products must be distinguished from unapproved or counterfeit copies. [1]
November 2026 safety update
FDA requires a warning about a potential increased risk of NAION, a rare optic-nerve condition that can cause permanent vision loss. Seek prompt medical attention for sudden painless vision loss or other visual changes. Individual labels may still be undergoing revision. [4]
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- FDA prescribing information: Mounjaro (revised January 2026)
- FDA prescribing information: Zepbound (revised February 2026)
- FDA · GLP-1 eye-safety notice · November 9, 2026
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.